Investor Relations

News Releases

Date Title and Summary Additional Formats
Toggle Summary Anika Completes Enrollment in Second Pivotal Phase III Trial of CINGAL for the Treatment of Knee Pain Associated with Osteoarthritis
BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc . (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced the completion of enrollment in its second pivotal Phase III
View HTML
Toggle Summary Anika Announces the Forthcoming Appointment of Thomas M. Finnerty as Chief Human Resources Officer
BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced the appointment of Thomas M.
View HTML
Toggle Summary Anika Announces Regulatory Approval for MONOVISC® in Australia for the Treatment of Pain Associated with Osteoarthritis of all Synovial Joints
BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced that regulatory authorities in Australia granted approval to
View HTML
Toggle Summary Anika to Issue Third-Quarter 2017 Financial Results and Business Highlights on Wednesday, October 25
BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its third-quarter 2017 financial results after the close of the market on Wednesday, October 25, 2017 and to hold a conference call the next day, Thursday, October 26, 2017 ,
View HTML
Toggle Summary Anika Announces Appointment of Steven Chartier as Vice President of Regulatory and Clinical Affairs
Deep international expertise to drive the Company's global expansion BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today
View HTML
Toggle Summary Anika Announces Publication of Data Demonstrating the Efficacy and Safety of HYALOFAST® in Combination with Stem Cells for the Treatment of Cartilage Lesions on the Knee
BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced the publication of data demonstrating that HYALOFAST ® , a
View HTML
Toggle Summary Anika Announces Appointment of Joseph Darling as President
Track Record of Successful Product Launch and Global Commercial Expansion BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today
View HTML
Toggle Summary Anika Reports Strong Second Quarter 2017 Financial Results
MONOVISC U.S. End-User Sales Exceeded $100 Million at an Accelerated Pace CINGAL Phase III Clinical Trial Achieved Rapid Advancements BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on
View HTML
Toggle Summary Anika Announces Regulatory Approval for MONOVISC® in India for the Treatment of Pain Associated with Osteoarthritis of All Synovial Joints
BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced that regulatory authorities in India granted approval to MONOVISC
View HTML
Toggle Summary Anika Announces $5 Million Milestone Payment from U.S. Commercial Sales of MONOVISC
Company Expects Total Revenue Growth of 23% to 26% for Q2 2017 BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced
View HTML